The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Subscribe To Our Newsletter & Stay Updated
